Ajovy and Emgality Comparison

Ajovy®(fremanezumab)	Emgality®(galcanezumab-gnlm)
Prescription Only Ajovy is a prescription medication that can be self-injected once a month or once every three months under the skin to prevent migraine headaches. The most commonly reported side...	Prescription Only Emgality is a medication that can be self-administered once a month by injecting it subcutaneously under the skin. It is used for migraine prevention in adults and can also be...
Administration
Subcutaneous. Learn more.	Subcutaneous. Learn more.
Dosing
225 mg monthly or 675 mg every 3 months (as three consecutive injections of 225 mg each). Learn more.	Migraine: 240 mg loading dose (120 mg x 2) followed by 120 mg monthly. . Learn more.
Latin Shorthand
225 mg/mo or 675 mg q3mo. Learn more.	240 mg LD (120 mg x 2) then 120 mg/mo.. Learn more.
Out-Of-Pocket Costs With Copay Card
$5. Learn more.	$0. Learn more.
Annual Cap
Patient specific maximum benefit.. Learn more.	$4900. Learn more.
Assistance Expiration
12/31/2023. Learn more.	12 months. Learn more.
Generics
No lower-cost generic available	No lower-cost generic available
Adverse Reactions
The most common adverse reactions (≥5% and greater than placebo) were injection site reactions.. Learn more.	The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in EMGALITY clinical studies were injection site reactions. . Learn more.
Mechanism of Actions (MoA)
CGRP Antagonist. Learn more.	CGRP Antagonist. Learn more.
Special Populations
Is there a pregnancy exposure registry for AJOVY? Yes, there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to AJOVY during pregnancy. Healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves in the registry by calling 1-833-927-2605 or visiting www.tevamigrainepregnancyregistry.com. What is the risk associated with the use of AJOVY during pregnancy? There are no adequate data on the developmental risk associated with the use of AJOVY in pregnant women. AJOVY has a long half-life, which should be taken into consideration for women who are pregnant or plan to become pregnant while using AJOVY. However, administration of fremanezumab-vfrm (the active ingredient in AJOVY) to rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation at doses resulting in plasma levels greater than those expected clinically did not result in adverse effects on development. What is the estimated background risk of major birth defects and miscarriage for the indicated population? The estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively, for the U.S. general population. The estimated rate of major birth defects and miscarriage among deliveries to women with migraine are similar to rates reported in women without migraine. Is AJOVY safe to use during lactation? There are no data on the presence of fremanezumab-vfrm (the active ingredient in AJOVY) in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for AJOVY and any potential adverse effects on the breastfed infant from AJOVY or from the underlying maternal condition. Is AJOVY safe and effective for use in pediatric patients? Safety and effectiveness in pediatric patients have not been established. Is there any information on the use of AJOVY in geriatric patients? Clinical studies of AJOVY did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.	What is the Pregnancy Exposure Registry for EMGALITY? The Pregnancy Exposure Registry is a program that monitors pregnancy outcomes in women who have been exposed to EMGALITY during pregnancy. It is designed to collect information on any potential risks to the developing fetus. How can pregnant women enroll in the Pregnancy Exposure Registry? Pregnant women can enroll in the registry by calling 1-833-464-4724 or by contacting the company at www.migrainepregnancyregistry.com. What is the estimated risk of major birth defects and miscarriage in the general population and among women with migraine? The estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively, in the general population. The estimated rate of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. Are there any known risks associated with the use of EMGALITY during pregnancy? There are no adequate data on the developmental risk associated with the use of EMGALITY in pregnant women. However, animal studies have shown that administration of galcanezumab-gnlm to rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation at plasma exposures greater than that expected clinically did not result in adverse effects on development. Can EMGALITY be used during lactation? There are no data on the presence of galcanezumab-gnlm in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EMGALITY and any potential adverse effects on the breastfed infant from EMGALITY or from the underlying maternal condition. Is EMGALITY safe for pediatric use? Safety and effectiveness in pediatric patients have not been established. Is there any difference in the response to EMGALITY in geriatric patients compared to younger patients? Clinical studies of EMGALITY did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.

Ajovy®(fremanezumab)

Emgality®(galcanezumab-gnlm)

Prescription Only

Ajovy is a prescription medication that can be self-injected once a month or once every three months under the skin to prevent migraine headaches. The most commonly reported side...

Prescription Only

Emgality is a medication that can be self-administered once a month by injecting it subcutaneously under the skin. It is used for migraine prevention in adults and can also be...

Dosage & Administration

Administration

Subcutaneous. Learn more.

Dosing

225 mg monthly or 675 mg every 3 months (as three consecutive injections of 225 mg each). Learn more.

Migraine: 240 mg loading dose (120 mg x 2) followed by 120 mg monthly. . Learn more.

Latin Shorthand

225 mg/mo or 675 mg q3mo. Learn more.

240 mg LD (120 mg x 2) then 120 mg/mo.. Learn more.

Financial Assistance

Out-Of-Pocket Costs With Copay Card

$5. Learn more.

$0. Learn more.

Annual Cap

Patient specific maximum benefit.. Learn more.

$4900. Learn more.

Assistance Expiration

12/31/2023. Learn more.

12 months. Learn more.

Generics

No lower-cost generic available

Physician Advisory

Adverse Reactions

The most common adverse reactions (≥5% and greater than placebo) were injection site reactions.. Learn more.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in EMGALITY clinical studies were injection site reactions. . Learn more.

Mechanism of Actions (MoA)

CGRP Antagonist. Learn more.

Special Populations

Is there a pregnancy exposure registry for AJOVY?

Yes, there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to AJOVY during pregnancy. Healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves in the registry by calling 1-833-927-2605 or visiting www.tevamigrainepregnancyregistry.com.

What is the risk associated with the use of AJOVY during pregnancy?

There are no adequate data on the developmental risk associated with the use of AJOVY in pregnant women. AJOVY has a long half-life, which should be taken into consideration for women who are pregnant or plan to become pregnant while using AJOVY. However, administration of fremanezumab-vfrm (the active ingredient in AJOVY) to rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation at doses resulting in plasma levels greater than those expected clinically did not result in adverse effects on development.

What is the estimated background risk of major birth defects and miscarriage for the indicated population?

The estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively, for the U.S. general population. The estimated rate of major birth defects and miscarriage among deliveries to women with migraine are similar to rates reported in women without migraine.

Is AJOVY safe to use during lactation?

There are no data on the presence of fremanezumab-vfrm (the active ingredient in AJOVY) in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for AJOVY and any potential adverse effects on the breastfed infant from AJOVY or from the underlying maternal condition.

Is AJOVY safe and effective for use in pediatric patients?

Safety and effectiveness in pediatric patients have not been established.

Is there any information on the use of AJOVY in geriatric patients?

Clinical studies of AJOVY did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

What is the Pregnancy Exposure Registry for EMGALITY?

The Pregnancy Exposure Registry is a program that monitors pregnancy outcomes in women who have been exposed to EMGALITY during pregnancy. It is designed to collect information on any potential risks to the developing fetus.

How can pregnant women enroll in the Pregnancy Exposure Registry?

Pregnant women can enroll in the registry by calling 1-833-464-4724 or by contacting the company at www.migrainepregnancyregistry.com.

What is the estimated risk of major birth defects and miscarriage in the general population and among women with migraine?

The estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively, in the general population. The estimated rate of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine.

Are there any known risks associated with the use of EMGALITY during pregnancy?

There are no adequate data on the developmental risk associated with the use of EMGALITY in pregnant women. However, animal studies have shown that administration of galcanezumab-gnlm to rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation at plasma exposures greater than that expected clinically did not result in adverse effects on development.

Can EMGALITY be used during lactation?

There are no data on the presence of galcanezumab-gnlm in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EMGALITY and any potential adverse effects on the breastfed infant from EMGALITY or from the underlying maternal condition.

Is EMGALITY safe for pediatric use?

Safety and effectiveness in pediatric patients have not been established.

Is there any difference in the response to EMGALITY in geriatric patients compared to younger patients?

Clinical studies of EMGALITY did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.

Ajovy® Alternatives